Results 51 to 60 of about 780 (156)

The efficacy of azvudine in treating hospitalized COVID-19 patients: a retrospective single-center cohort analysis. [PDF]

J Thorac Dis
Lei H, Ye YW, Zhou YJ, Mao YF, Fang Y, Chen PP, You WW, Li S, Xu YY.   +8 more
europepmc   +2 more sources

HIV and SARS-CoV-2 Co-Infection: From Population Study Evidence to In Vitro Studies [PDF]

, 2022
Human immunodeficiency virus type 1 (HIV-1) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have caused two major viral outbreaks during the last century.
Bissoli, Michele, Fantoni, Tobia, Ruggiero, Alessandra, Stefani, Chiara, Thomas, Jordan   +4 more
core   +2 more sources

Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro.

PLoS ONE, 2014
Azvudine is a novel nucleoside reverse transcriptase inhibitor with antiviral activity on human immunodeficiency virus, hepatitis B virus and hepatitis C virus. Here we reported the in vitro activity of azvudine against HIV-1 and HIV-2 when used alone or
Rui-Rui Wang, Qing-Hua Yang, Rong-Hua Luo, You-Mei Peng, Shao-Xing Dai, Xing-Jie Zhang, Huan Chen, Xue-Qing Cui, Ya-Juan Liu, Jing-Fei Huang, Jun-Biao Chang, Yong-Tang Zheng   +11 more
doaj   +1 more source

Association of eosinopenia with worsening prognosis in hospitalized Azvudine-treated COVID-19 patients: a retrospective cohort study

Frontiers in Immunology, 2023
BackgroundCurrent guidelines prioritize the use of Azvudine in Coronavirus Disease 2019 (COVID-19) patients, while biomarkers for prognosis in Azvudine-treated COVID-19 patients are still lacking.
Xiaomin Wang, Xiaomin Wang, Xiaomin Wang, Xiaomin Wang, Xiaomin Wang, Xiaomin Wang, Xiaomin Wang, Yating Dian, Yating Dian, Yating Dian, Yating Dian, Yating Dian, Qian Zhou, Qian Zhou, Qian Zhou, Qian Zhou, Qian Zhou, Guangtong Deng, Guangtong Deng, Guangtong Deng, Guangtong Deng, Guangtong Deng, Rui Wei, Rui Wei, Furong Zeng, Furong Zeng   +25 more
doaj   +1 more source

Drug repurposing in the treatment of COVID-19: A review [PDF]

, 2021
The first outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was in Wuhan, Hubei, China in December 2019 and declared as a pandemic by the World Health Organization.
Madhuri, D. Game, Sonali, S. Gadge, Vikrant, L. Salode   +2 more
core   +2 more sources

How COVID-19 has fundamentally changed clinical research in global health [PDF]

, 2021
COVID-19 has had negative repercussions on the entire global population. Despite there being a common goal that should have unified resources and efforts, there have been an overwhelmingly large number of clinical trials that have been registered that ...
Condo, Jeanine, Decloedt, Eric H, Jehan, Fyezah, Mills, Edward J, Mogg, Robin, Nachega, Jean B, Nakimuli-Mpungu, Etheldreda, Park, Jay J H, Rayner, Craig R, Reis, Gilmar, Smith, Gerald E   +10 more
core   +5 more sources

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system [PDF]

, 2023
Molnupiravir, an urgently approved drug during the Coronavirus Disease 2019 (COVID-19) pandemic, serves as the basis for our study, which relies on the Food and Drug Administration Adverse Event Reporting System (FAERS).
Jingping Zheng, Jun Lyu, Jun Lyu, Lin Ma, Ling Su, Yankun Liang, Yankun Liang, Yuting Wang   +7 more
core   +1 more source

Clinical Characteristics of SARS-COV-2 Omicron Variant in Acute Myeloid Leukemia and Acute Lymphocytic Leukemia Patients: A Multi-Center Retrospective Study. [PDF]

Cancer Rep (Hoboken)
ABSTRACT Background The death rate of hematological malignancies is high, and the death rate of patients with COVID‐19 infection is further increased. Although there have been expert consensus and relevant guidelines to introduce the recommendations of the guidelines for patients with hematological malignancies complicated with COVID‐19 infection ...
Wang L, Mi R, Chen L, Liu J, Yang H, Hu M, Xiaoqiang Z, Zhang Y, Xu X, Liu B, Zhao H, Qianyu L, Liu T, Zhenzhu C, Yao J, Yang Y, Wei X.   +16 more
europepmc   +2 more sources

Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients [PDF]

, 2023
Background: Scarce data exist that analyze the outcomes of hematological patients with SARS-CoV-2 infection during the Omicron variant period who received treatment with remdesivir or nirmatrelvir/ritonavir. Methods: This study aims to address this issue
Piñana, José Luis, Heras, Inmaculada, Aiello, Tommaso Francesco, Garcia Cadenas, Irene, Vazquez, Lourdes, Lopez-Jimenez, Javier, Chorão, Pedro, Aroca, Cristina, Garcia-Vidal, Carolina, Arroyo, Ignacio, Soler-Espejo, Eva, López Corral, Lucia, Avendaño-Pita, Alejandro, Arrufat, Anna, Garcia-Gutierrez, Valentin, Arellano, Elena, Hernández-Medina, Lorena, González-Santillana, Clara, Morell, Julia, Hernández Rivas, José Ángel, Rodriguez-Galvez, Paula, Mico-Cerdá, Mireia, Guerreiro, Manuel, Campos, Diada, Navarro, David, Cedillo, Ángel, Martino Bofarull, Rodrigo, Solano, Carlos, Universitat Autònoma de Barcelona   +28 more
core   +2 more sources

Antiviral Effectiveness, Clinical Outcomes, and Artificial Intelligence Imaging Analysis for Hospitalized COVID-19 Patients Receiving Antivirals. [PDF]

Influenza Other Respir Viruses
ABSTRACT Introduction There is still a lack of clinical evidence comprehensively evaluating the effectiveness of antiviral treatments for COVID‐19 hospitalized patients. Methods A retrospective cohort study was conducted at Beijing You'An Hospital, focusing on patients treated with nirmatrelvir/ritonavir or azvudine.
Gao Y, Dong Y, Bu Q, Gong Z, Wang W, Zhou Z, Gao Y, Liu L, Wu M, Zhang J, Liang L, Li H, Jiang M, Luo Z, Ma Y, Zhang X, Hu Z.   +16 more
europepmc   +2 more sources